---
bibliography: 'morinlab.bib'
csl: 'NLM.csl'
link-citations: true
nocite: |
  @mottokIntegrativeGenomicAnalysis2019, @rushtonGeneticEvolutionaryPatterns2020, 
---
[[_TOC_]]

## Overview
MS4A1 encodes the CD20 protein, which is the target of rituximab and other therapeutic monoclonal antibodies. 
MS4A1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, 
which complicates the interpretation of mutations at this locus. 
In relapsed DLBCLs, MS4A1 is sometimes mutated and these mutations have been shown to reduce CD20 expression.[@rushtonGeneticEvolutionaryPatterns2020]


## Experimental Evidence

Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a reduction or loss of function (LOF).[@rushtonGeneticEvolutionaryPatterns2020]

## Relevance tier by entity

[[include:table1_MS4A1.md]]

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

### DLBCL
[[include:DLBCL_MS4A1.md]]

## Mutation pattern and selective pressure estimates

[[include:dnds_MS4A1.md]]

## aSHM regions

|chr_name|hg19_start|hg19_end|region                                                                                    |regulatory_comment|
|:--------:|:----------:|:--------:|:------------------------------------------------------------------------------------------:|:------------------:|
|chr11   |60223385  |60225310|[TSS](https://genome.ucsc.edu/s/rdmorin/GAMBL%20hg19?position=chr11%3A60223385%2D60225310)|active_promoter   |


[[include:browser_MS4A1.md]]

## Expression
![](images/gene_expression/MS4A1_by_pathology.svg)

[[include:mermaid_MS4A1.md]]

## References
<!-- ORIGIN: mottokIntegrativeGenomicAnalysis2019b -->
<!-- DLBCL: rushtonGeneticEvolutionaryPatterns2020 -->
<!-- PMBL: mottokIntegrativeGenomicAnalysis2019b -->
